Hemodynamic observations in two pulmonary hypertensive patients changing treatment from inhaled iloprost to the oral endothelin-antagonist bosentan.
Two female patients with pulmonary arterial hypertension and a permanently implanted hemodynamic monitor changed treatment from inhaled iloprost to oral bosentan. The hemodynamic changes were seen very early after the first dose of bosentan and there was no need to re-establish inhaled iloprost.
Fruhwald
Friedrich M
FM
Department of Medicine, Division of Cardiology, Medical University, Graz, Austria. friedrich.fruhwald@meduni-graz.at
Kjellström
Barbro
B
Perthold
Wolfgang
W
Wonisch
Manfred
M
Maier
Robert
R
Klein
Werner
W
D000280:Administration, Inhalation; D000284:Administration, Oral; D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage*; D000077300:Bosentan; D065128:Endothelin Receptor Antagonists; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000503:physiopathology*; D016285:Iloprost / Q000008:administration & dosage*; D008875:Middle Aged; D018670:Monitoring, Ambulatory / Q000295:instrumentation; D019736:Prostheses and Implants; D013449:Sulfonamides / Q000008:administration & dosage*
D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D013449:Sulfonamides; D016285:Iloprost; D000077300:Bosentan